Global 23-valent Pneumococcal Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 325162
  • calendar_today Published On: Jan, 2023
  • file_copy Pages: 165
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The 23-valent Pneumococcal Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global 23-valent Pneumococcal Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Chronic Cardiovascular Disease accounting for % of the 23-valent Pneumococcal Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Single Dose Vial segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of 23-valent Pneumococcal Vaccine include Merck, Sanofipasteur, CDIBP, Kexing Bio, and Changsheng Bio-Technology, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

23-valent Pneumococcal Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Single Dose Vial

Pre-filled Syringe

Market segment by Application can be divided into

Chronic Cardiovascular Disease

Chronic Lung Disease

Chronic Liver Disease

People Living with Hiv

Leukemia

Lymphoma

Multiple Myeloma

General Malignancy

Chronic Kidney Disease

Other

The key market players for global 23-valent Pneumococcal Vaccine market are listed below:

Merck

Sanofipasteur

CDIBP

Kexing Bio

Changsheng Bio-Technology

Huaan Science and Technology Innovation

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe 23-valent Pneumococcal Vaccine product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of 23-valent Pneumococcal Vaccine, with price, sales, revenue and global market share of 23-valent Pneumococcal Vaccine from 2019 to 2022.

Chapter 3, the 23-valent Pneumococcal Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the 23-valent Pneumococcal Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and 23-valent Pneumococcal Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of 23-valent Pneumococcal Vaccine.

Chapter 13, 14, and 15, to describe 23-valent Pneumococcal Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 23-valent Pneumococcal Vaccine Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global 23-valent Pneumococcal Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028

1.2.2 Single Dose Vial

1.2.3 Pre-filled Syringe

1.3 Market Analysis by Application

1.3.1 Overview: Global 23-valent Pneumococcal Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028

1.3.2 Chronic Cardiovascular Disease

1.3.3 Chronic Lung Disease

1.3.4 Chronic Liver Disease

1.3.5 People Living with Hiv

1.3.6 Leukemia

1.3.7 Lymphoma

1.3.8 Multiple Myeloma

1.3.9 General Malignancy

1.3.10 Chronic Kidney Disease

1.3.11 Other

1.4 Global 23-valent Pneumococcal Vaccine Market Size & Forecast

1.4.1 Global 23-valent Pneumococcal Vaccine Sales in Value (2017 & 2021 & 2028)

1.4.2 Global 23-valent Pneumococcal Vaccine Sales in Volume (2017-2028)

1.4.3 Global 23-valent Pneumococcal Vaccine Price (2017-2028)

1.5 Global 23-valent Pneumococcal Vaccine Production Capacity Analysis

1.5.1 Global 23-valent Pneumococcal Vaccine Total Production Capacity (2017-2028)

1.5.2 Global 23-valent Pneumococcal Vaccine Production Capacity by Geographic Region

1.6 Market Drivers, Restraints and Trends

1.6.1 23-valent Pneumococcal Vaccine Market Drivers

1.6.2 23-valent Pneumococcal Vaccine Market Restraints

1.6.3 23-valent Pneumococcal Vaccine Trends Analysis

2 Manufacturers Profiles

2.1 Merck

2.1.1 Merck Details

2.1.2 Merck Major Business

2.1.3 Merck 23-valent Pneumococcal Vaccine Product and Services

2.1.4 Merck 23-valent Pneumococcal Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2 Sanofipasteur

2.2.1 Sanofipasteur Details

2.2.2 Sanofipasteur Major Business

2.2.3 Sanofipasteur 23-valent Pneumococcal Vaccine Product and Services

2.2.4 Sanofipasteur 23-valent Pneumococcal Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3 CDIBP

2.3.1 CDIBP Details

2.3.2 CDIBP Major Business

2.3.3 CDIBP 23-valent Pneumococcal Vaccine Product and Services

2.3.4 CDIBP 23-valent Pneumococcal Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4 Kexing Bio

2.4.1 Kexing Bio Details

2.4.2 Kexing Bio Major Business

2.4.3 Kexing Bio 23-valent Pneumococcal Vaccine Product and Services

2.4.4 Kexing Bio 23-valent Pneumococcal Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5 Changsheng Bio-Technology

2.5.1 Changsheng Bio-Technology Details

2.5.2 Changsheng Bio-Technology Major Business

2.5.3 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product and Services

2.5.4 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6 Huaan Science and Technology Innovation

2.6.1 Huaan Science and Technology Innovation Details

2.6.2 Huaan Science and Technology Innovation Major Business

2.6.3 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product and Services

2.6.4 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 23-valent Pneumococcal Vaccine Breakdown Data by Manufacturer

3.1 Global 23-valent Pneumococcal Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global 23-valent Pneumococcal Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in 23-valent Pneumococcal Vaccine

3.4 Market Concentration Rate

3.4.1 Top 3 23-valent Pneumococcal Vaccine Manufacturer Market Share in 2021

3.4.2 Top 6 23-valent Pneumococcal Vaccine Manufacturer Market Share in 2021

3.5 Global 23-valent Pneumococcal Vaccine Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and 23-valent Pneumococcal Vaccine Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers & Acquisitions

4 Market Analysis by Region

4.1 Global 23-valent Pneumococcal Vaccine Market Size by Region

4.1.1 Global 23-valent Pneumococcal Vaccine Sales in Volume by Region (2017-2028)

4.1.2 Global 23-valent Pneumococcal Vaccine Revenue by Region (2017-2028)

4.2 North America 23-valent Pneumococcal Vaccine Revenue (2017-2028)

4.3 Europe 23-valent Pneumococcal Vaccine Revenue (2017-2028)

4.4 Asia-Pacific 23-valent Pneumococcal Vaccine Revenue (2017-2028)

4.5 South America 23-valent Pneumococcal Vaccine Revenue (2017-2028)

4.6 Middle East and Africa 23-valent Pneumococcal Vaccine Revenue (2017-2028)

5 Market Segment by Type

5.1 Global 23-valent Pneumococcal Vaccine Sales in Volume by Type (2017-2028)

5.2 Global 23-valent Pneumococcal Vaccine Revenue by Type (2017-2028)

5.3 Global 23-valent Pneumococcal Vaccine Price by Type (2017-2028)

6 Market Segment by Application

6.1 Global 23-valent Pneumococcal Vaccine Sales in Volume by Application (2017-2028)

6.2 Global 23-valent Pneumococcal Vaccine Revenue by Application (2017-2028)

6.3 Global 23-valent Pneumococcal Vaccine Price by Application (2017-2028)

7 North America by Country, by Type, and by Application

7.1 North America 23-valent Pneumococcal Vaccine Sales by Type (2017-2028)

7.2 North America 23-valent Pneumococcal Vaccine Sales by Application (2017-2028)

7.3 North America 23-valent Pneumococcal Vaccine Market Size by Country

7.3.1 North America 23-valent Pneumococcal Vaccine Sales in Volume by Country (2017-2028)

7.3.2 North America 23-valent Pneumococcal Vaccine Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Application

8.1 Europe 23-valent Pneumococcal Vaccine Sales by Type (2017-2028)

8.2 Europe 23-valent Pneumococcal Vaccine Sales by Application (2017-2028)

8.3 Europe 23-valent Pneumococcal Vaccine Market Size by Country

8.3.1 Europe 23-valent Pneumococcal Vaccine Sales in Volume by Country (2017-2028)

8.3.2 Europe 23-valent Pneumococcal Vaccine Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Application

9.1 Asia-Pacific 23-valent Pneumococcal Vaccine Sales by Type (2017-2028)

9.2 Asia-Pacific 23-valent Pneumococcal Vaccine Sales by Application (2017-2028)

9.3 Asia-Pacific 23-valent Pneumococcal Vaccine Market Size by Region

9.3.1 Asia-Pacific 23-valent Pneumococcal Vaccine Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific 23-valent Pneumococcal Vaccine Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

10 South America by Region, by Type, and by Application

10.1 South America 23-valent Pneumococcal Vaccine Sales by Type (2017-2028)

10.2 South America 23-valent Pneumococcal Vaccine Sales by Application (2017-2028)

10.3 South America 23-valent Pneumococcal Vaccine Market Size by Country

10.3.1 South America 23-valent Pneumococcal Vaccine Sales in Volume by Country (2017-2028)

10.3.2 South America 23-valent Pneumococcal Vaccine Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East & Africa by Country, by Type, and by Application

11.1 Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Type (2017-2028)

11.2 Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Application (2017-2028)

11.3 Middle East & Africa 23-valent Pneumococcal Vaccine Market Size by Country

11.3.1 Middle East & Africa 23-valent Pneumococcal Vaccine Sales in Volume by Country (2017-2028)

11.3.2 Middle East & Africa 23-valent Pneumococcal Vaccine Revenue by Country (2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain

12.1 Raw Material of 23-valent Pneumococcal Vaccine and Key Manufacturers

12.2 Manufacturing Costs Percentage of 23-valent Pneumococcal Vaccine

12.3 23-valent Pneumococcal Vaccine Production Process

12.4 23-valent Pneumococcal Vaccine Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 23-valent Pneumococcal Vaccine Typical Distributors

13.3 23-valent Pneumococcal Vaccine Typical Customers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

List of Tables

Table 1. Global 23-valent Pneumococcal Vaccine Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 2. Global 23-valent Pneumococcal Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 3. Merck Basic Information, Manufacturing Base and Competitors

Table 4. Merck Major Business

Table 5. Merck 23-valent Pneumococcal Vaccine Product and Services

Table 6. Merck 23-valent Pneumococcal Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 7. Sanofipasteur Basic Information, Manufacturing Base and Competitors

Table 8. Sanofipasteur Major Business

Table 9. Sanofipasteur 23-valent Pneumococcal Vaccine Product and Services

Table 10. Sanofipasteur 23-valent Pneumococcal Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 11. CDIBP Basic Information, Manufacturing Base and Competitors

Table 12. CDIBP Major Business

Table 13. CDIBP 23-valent Pneumococcal Vaccine Product and Services

Table 14. CDIBP 23-valent Pneumococcal Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 15. Kexing Bio Basic Information, Manufacturing Base and Competitors

Table 16. Kexing Bio Major Business

Table 17. Kexing Bio 23-valent Pneumococcal Vaccine Product and Services

Table 18. Kexing Bio 23-valent Pneumococcal Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 19. Changsheng Bio-Technology Basic Information, Manufacturing Base and Competitors

Table 20. Changsheng Bio-Technology Major Business

Table 21. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product and Services

Table 22. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 23. Huaan Science and Technology Innovation Basic Information, Manufacturing Base and Competitors

Table 24. Huaan Science and Technology Innovation Major Business

Table 25. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product and Services

Table 26. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 27. Global 23-valent Pneumococcal Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)

Table 28. Global 23-valent Pneumococcal Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)

Table 29. Market Position of Manufacturers in 23-valent Pneumococcal Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021

Table 30. Global 23-valent Pneumococcal Vaccine Production Capacity by Company, (K Units): 2020 VS 2021

Table 31. Head Office and 23-valent Pneumococcal Vaccine Production Site of Key Manufacturer

Table 32. 23-valent Pneumococcal Vaccine New Entrant and Capacity Expansion Plans

Table 33. 23-valent Pneumococcal Vaccine Mergers & Acquisitions in the Past Five Years

Table 34. Global 23-valent Pneumococcal Vaccine Sales by Region (2017-2022) & (K Units)

Table 35. Global 23-valent Pneumococcal Vaccine Sales by Region (2023-2028) & (K Units)

Table 36. Global 23-valent Pneumococcal Vaccine Revenue by Region (2017-2022) & (USD Million)

Table 37. Global 23-valent Pneumococcal Vaccine Revenue by Region (2023-2028) & (USD Million)

Table 38. Global 23-valent Pneumococcal Vaccine Sales by Type (2017-2022) & (K Units)

Table 39. Global 23-valent Pneumococcal Vaccine Sales by Type (2023-2028) & (K Units)

Table 40. Global 23-valent Pneumococcal Vaccine Revenue by Type (2017-2022) & (USD Million)

Table 41. Global 23-valent Pneumococcal Vaccine Revenue by Type (2023-2028) & (USD Million)

Table 42. Global 23-valent Pneumococcal Vaccine Price by Type (2017-2022) & (US$/Unit)

Table 43. Global 23-valent Pneumococcal Vaccine Price by Type (2023-2028) & (US$/Unit)

Table 44. Global 23-valent Pneumococcal Vaccine Sales by Application (2017-2022) & (K Units)

Table 45. Global 23-valent Pneumococcal Vaccine Sales by Application (2023-2028) & (K Units)

Table 46. Global 23-valent Pneumococcal Vaccine Revenue by Application (2017-2022) & (USD Million)

Table 47. Global 23-valent Pneumococcal Vaccine Revenue by Application (2023-2028) & (USD Million)

Table 48. Global 23-valent Pneumococcal Vaccine Price by Application (2017-2022) & (US$/Unit)

Table 49. Global 23-valent Pneumococcal Vaccine Price by Application (2023-2028) & (US$/Unit)

Table 50. North America 23-valent Pneumococcal Vaccine Sales by Country (2017-2022) & (K Units)

Table 51. North America 23-valent Pneumococcal Vaccine Sales by Country (2023-2028) & (K Units)

Table 52. North America 23-valent Pneumococcal Vaccine Revenue by Country (2017-2022) & (USD Million)

Table 53. North America 23-valent Pneumococcal Vaccine Revenue by Country (2023-2028) & (USD Million)

Table 54. North America 23-valent Pneumococcal Vaccine Sales by Type (2017-2022) & (K Units)

Table 55. North America 23-valent Pneumococcal Vaccine Sales by Type (2023-2028) & (K Units)

Table 56. North America 23-valent Pneumococcal Vaccine Sales by Application (2017-2022) & (K Units)

Table 57. North America 23-valent Pneumococcal Vaccine Sales by Application (2023-2028) & (K Units)

Table 58. Europe 23-valent Pneumococcal Vaccine Sales by Country (2017-2022) & (K Units)

Table 59. Europe 23-valent Pneumococcal Vaccine Sales by Country (2023-2028) & (K Units)

Table 60. Europe 23-valent Pneumococcal Vaccine Revenue by Country (2017-2022) & (USD Million)

Table 61. Europe 23-valent Pneumococcal Vaccine Revenue by Country (2023-2028) & (USD Million)

Table 62. Europe 23-valent Pneumococcal Vaccine Sales by Type (2017-2022) & (K Units)

Table 63. Europe 23-valent Pneumococcal Vaccine Sales by Type (2023-2028) & (K Units)

Table 64. Europe 23-valent Pneumococcal Vaccine Sales by Application (2017-2022) & (K Units)

Table 65. Europe 23-valent Pneumococcal Vaccine Sales by Application (2023-2028) & (K Units)

Table 66. Asia-Pacific 23-valent Pneumococcal Vaccine Sales by Region (2017-2022) & (K Units)

Table 67. Asia-Pacific 23-valent Pneumococcal Vaccine Sales by Region (2023-2028) & (K Units)

Table 68. Asia-Pacific 23-valent Pneumococcal Vaccine Revenue by Region (2017-2022) & (USD Million)

Table 69. Asia-Pacific 23-valent Pneumococcal Vaccine Revenue by Region (2023-2028) & (USD Million)

Table 70. Asia-Pacific 23-valent Pneumococcal Vaccine Sales by Type (2017-2022) & (K Units)

Table 71. Asia-Pacific 23-valent Pneumococcal Vaccine Sales by Type (2023-2028) & (K Units)

Table 72. Asia-Pacific 23-valent Pneumococcal Vaccine Sales by Application (2017-2022) & (K Units)

Table 73. Asia-Pacific 23-valent Pneumococcal Vaccine Sales by Application (2023-2028) & (K Units)

Table 74. South America 23-valent Pneumococcal Vaccine Sales by Country (2017-2022) & (K Units)

Table 75. South America 23-valent Pneumococcal Vaccine Sales by Country (2023-2028) & (K Units)

Table 76. South America 23-valent Pneumococcal Vaccine Revenue by Country (2017-2022) & (USD Million)

Table 77. South America 23-valent Pneumococcal Vaccine Revenue by Country (2023-2028) & (USD Million)

Table 78. South America 23-valent Pneumococcal Vaccine Sales by Type (2017-2022) & (K Units)

Table 79. South America 23-valent Pneumococcal Vaccine Sales by Type (2023-2028) & (K Units)

Table 80. South America 23-valent Pneumococcal Vaccine Sales by Application (2017-2022) & (K Units)

Table 81. South America 23-valent Pneumococcal Vaccine Sales by Application (2023-2028) & (K Units)

Table 82. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Region (2017-2022) & (K Units)

Table 83. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Region (2023-2028) & (K Units)

Table 84. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue by Region (2017-2022) & (USD Million)

Table 85. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue by Region (2023-2028) & (USD Million)

Table 86. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Type (2017-2022) & (K Units)

Table 87. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Type (2023-2028) & (K Units)

Table 88. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Application (2017-2022) & (K Units)

Table 89. Middle East & Africa 23-valent Pneumococcal Vaccine Sales by Application (2023-2028) & (K Units)

Table 90. 23-valent Pneumococcal Vaccine Raw Material

Table 91. Key Manufacturers of 23-valent Pneumococcal Vaccine Raw Materials

Table 92. Direct Channel Pros & Cons

Table 93. Indirect Channel Pros & Cons

Table 94. 23-valent Pneumococcal Vaccine Typical Distributors

Table 95. 23-valent Pneumococcal Vaccine Typical Customers

List of Figures

Figure 1. 23-valent Pneumococcal Vaccine Picture

Figure 2. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type in 2021

Figure 3. Single Dose Vial

Figure 4. Pre-filled Syringe

Figure 5. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application in 2021

Figure 6. Chronic Cardiovascular Disease

Figure 7. Chronic Lung Disease

Figure 8. Chronic Liver Disease

Figure 9. People Living with Hiv

Figure 10. Leukemia

Figure 11. Lymphoma

Figure 12. Multiple Myeloma

Figure 13. General Malignancy

Figure 14. Chronic Kidney Disease

Figure 15. Global 23-valent Pneumococcal Vaccine Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028

Figure 16. Global 23-valent Pneumococcal Vaccine Revenue and Forecast (2017-2028) & (USD Million)

Figure 17. Global 23-valent Pneumococcal Vaccine Sales (2017-2028) & (K Units)

Figure 18. Global 23-valent Pneumococcal Vaccine Price (2017-2028) & (US$/Unit)

Figure 19. Global 23-valent Pneumococcal Vaccine Production Capacity (2017-2028) & (K Units)

Figure 20. Global 23-valent Pneumococcal Vaccine Production Capacity by Geographic Region: 2022 VS 2028

Figure 21. 23-valent Pneumococcal Vaccine Market Drivers

Figure 22. 23-valent Pneumococcal Vaccine Market Restraints

Figure 23. 23-valent Pneumococcal Vaccine Market Trends

Figure 24. Global 23-valent Pneumococcal Vaccine Sales Market Share by Manufacturer in 2021

Figure 25. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Manufacturer in 2021

Figure 26. 23-valent Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 27. Top 3 23-valent Pneumococcal Vaccine Manufacturer (Revenue) Market Share in 2021

Figure 28. Top 6 23-valent Pneumococcal Vaccine Manufacturer (Revenue) Market Share in 2021

Figure 29. Global 23-valent Pneumococcal Vaccine Sales Market Share by Region (2017-2028)

Figure 30. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2017-2028)

Figure 31. North America 23-valent Pneumococcal Vaccine Revenue (2017-2028) & (USD Million)

Figure 32. Europe 23-valent Pneumococcal Vaccine Revenue (2017-2028) & (USD Million)

Figure 33. Asia-Pacific 23-valent Pneumococcal Vaccine Revenue (2017-2028) & (USD Million)

Figure 34. South America 23-valent Pneumococcal Vaccine Revenue (2017-2028) & (USD Million)

Figure 35. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue (2017-2028) & (USD Million)

Figure 36. Global 23-valent Pneumococcal Vaccine Sales Market Share by Type (2017-2028)

Figure 37. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Type (2017-2028)

Figure 38. Global 23-valent Pneumococcal Vaccine Price by Type (2017-2028) & (US$/Unit)

Figure 39. Global 23-valent Pneumococcal Vaccine Sales Market Share by Application (2017-2028)

Figure 40. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Application (2017-2028)

Figure 41. Global 23-valent Pneumococcal Vaccine Price by Application (2017-2028) & (US$/Unit)

Figure 42. North America 23-valent Pneumococcal Vaccine Sales Market Share by Type (2017-2028)

Figure 43. North America 23-valent Pneumococcal Vaccine Sales Market Share by Application (2017-2028)

Figure 44. North America 23-valent Pneumococcal Vaccine Sales Market Share by Country (2017-2028)

Figure 45. North America 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2017-2028)

Figure 46. United States 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. Canada 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Mexico 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Type (2017-2028)

Figure 50. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Application (2017-2028)

Figure 51. Europe 23-valent Pneumococcal Vaccine Sales Market Share by Country (2017-2028)

Figure 52. Europe 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2017-2028)

Figure 53. Germany 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. France 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. United Kingdom 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Russia 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Italy 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Asia-Pacific 23-valent Pneumococcal Vaccine Sales Market Share by Region (2017-2028)

Figure 59. Asia-Pacific 23-valent Pneumococcal Vaccine Sales Market Share by Application (2017-2028)

Figure 60. Asia-Pacific 23-valent Pneumococcal Vaccine Sales Market Share by Region (2017-2028)

Figure 61. Asia-Pacific 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2017-2028)

Figure 62. China 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Japan 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Korea 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. India 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Southeast Asia 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Australia 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. South America 23-valent Pneumococcal Vaccine Sales Market Share by Type (2017-2028)

Figure 69. South America 23-valent Pneumococcal Vaccine Sales Market Share by Application (2017-2028)

Figure 70. South America 23-valent Pneumococcal Vaccine Sales Market Share by Country (2017-2028)

Figure 71. South America 23-valent Pneumococcal Vaccine Revenue Market Share by Country (2017-2028)

Figure 72. Brazil 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. Argentina 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Type (2017-2028)

Figure 75. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Application (2017-2028)

Figure 76. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Market Share by Region (2017-2028)

Figure 77. Middle East & Africa 23-valent Pneumococcal Vaccine Revenue Market Share by Region (2017-2028)

Figure 78. Turkey 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. Egypt 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Saudi Arabia 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. South Africa 23-valent Pneumococcal Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. Manufacturing Cost Structure Analysis of 23-valent Pneumococcal Vaccine in 2021

Figure 83. Manufacturing Process Analysis of 23-valent Pneumococcal Vaccine

Figure 84. 23-valent Pneumococcal Vaccine Industrial Chain

Figure 85. Sales Channel: Direct Channel vs Indirect Channel

Figure 86. Methodology

Figure 87. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz